February 27, 2025 | Dovetail Genomics announced its early access services for FFPE (Formalin-Fixed Paraffin-Embedded) sample analysis; Cellino announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry; and more.
Royal Philips has launched SmartSpeed Precise, powered by Dual-AI engines. SmartSpeed Precise significantly improves scan speed and diagnostic image quality, extending AI-driven efficiency across the entire Philips MR portfolio, including existing customer systems. There is also the latest MR Workspace software release 12, which streamlines workflows and empowers clinicians to deliver faster, more accurate diagnoses. Press release.
OncoHost announced a collaboration with Gustave Roussy to identify non-invasive biomarkers for immune-related adverse events (irAEs) in patients undergoing immunotherapy. The PREMIS study, promoted by Gustave Roussy, is an interventional research aimed at identifying predictive biomarkers for irAEs in patients receiving immunotherapy. OncoHost is partnering with Gustave Roussy to further validate its PROphetirAE test, an advanced tool that utilizes AI and biomarker analysis to assess patients' risk of developing irAEs. The study's goal is to enable personalized treatment strategies that minimize toxicities and improve therapeutic outcomes. Press release.
Dovetail Genomics announced its early access services for FFPE (Formalin-Fixed Paraffin-Embedded) sample analysis, offering new capabilities for detecting structural variants and profiling RNA in oncology research. This service includes the detection of structural variants using Dovetail's proprietary linked-read chemistry, along with RNA profiling to validate gene fusion events and assess gene transcription levels. These technologies provide a comprehensive approach to uncovering structural variation and its impact on cancer-related transcriptional output. Press release.
Women’s cardiovascular health is shaped by unique risks, from hormonal changes to the impact of cancer treatments. Proactive monitoring and personalized care are essential. InfoBionic.Ai’s MoMe ARC delivers real-time cardiac insights, empowering physicians to improve patient outcomes. A recent study published in the Journal of the American Medical Association (JAMA) suggests a link between cardiovascular disease (CVD) and breast cancer. The case-control study found that women with cardiovascular disease were more likely to be diagnosed with advanced-stage breast cancer, specifically hormone receptor-positive, ERBB2-negative (formerly HER2-negative) subtypes. Press release.
Cellino announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute (GCTI) to launch the world’s first hospital-based autologous induced pluripotent stem cell (iPSC) Foundry. Powered by Cellino’s AI-driven Nebula technology, this initiative sets the stage for a nationwide network of decentralized biomanufacturing hubs designed to deliver personalized cell and tissue therapies directly at the point of care. Press release.
A team led by Mount Sinai researchers has identified stem cell populations and mechanisms underlying age-related degeneration in glands that are vital to eye function. The findings, published in Nature Communications on February 15, may lead to new therapeutic approaches for evaporative dry eye disease, a common condition in older people. Press release.
Seonix Bio announced the US launch of SightScore, the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma. SightScore uses a saliva test to identify individuals at high risk for glaucoma, enabling earlier diagnosis, intervention, and more personalized treatment while also identifying low-risk individuals who may benefit from less frequent monitoring. Press release.
The North-South partnership between the Genomic Surveillance Unit (GSU) at the Wellcome Sanger Institute and the Centre for Epidemic Response and Innovation (CERI) at Stellenbosch University (SU) has received funding under the UK Foreign, Commonwealth & Development Office’s (FCDO) UK-SA Health System Strengthening Partnership. The new project will leverage genomic surveillance to monitor respiratory viruses, like influenza, metapneumovirus, respiratory syncytial virus (RSV), and SARS-CoV-2 in real-time to boost pandemic preparedness in both the United Kingdom and South Africa. The partnership will focus on genomic monitoring of respiratory viruses, which are key culprits behind seasonal infections and potential pandemics. This initiative underscores the vital role of data sharing and international collaboration to create a unified, robust surveillance system for faster, more coordinated responses to emerging global health threats. By gathering genomic data on respiratory viruses over two winters in the same year, the project will advance seasonal disease preparedness and provide a unique window on the global spread of disease. Press release.
AlidaBio announced the full commercial launch of its EpiPlex platform, the first to concurrently detect and quantify multiple RNA modifications by short-read sequencing in addition to providing gene expression data. The platform, which pairs the EpiPlex RNA Reagent Kit and the EpiScout Analysis Suite, provides a comprehensive, single-workflow solution to advance research into the role of RNA modifications in disease, aging and development. The EpiPlex platform is designed to allow researchers of all skill levels to accurately and simultaneously detect multiple RNA modifications (N6-methyladenosine and inosine initially, with extendability to others), offering broader insights into the complex relationships between the modifications and dynamic regulatory mechanisms in cancer, neurological and cardiometabolic disease, cell differentiation, viral infection and other phenotypes relevant to human health. Press release.
Flatiron Health and Exact Sciences announced a strategic partnership aimed at accelerating clinical evidence generation for Exact Sciences’ molecular residual disease test (MRD), Oncodetect. The partnership leverages Flatiron’s leading-edge clinical research platform to study a broad range of solid tumor types. The companies have already achieved first patient enrolled. They aim to generate clinical evidence within a real-world setting and diverse patient populations by utilizing community care settings, typically underrepresented in clinical trials. This is particularly important in the emerging space of MRD, where oncologists continue to explore how these tests can integrate into delivering high-quality, precision cancer care. Press release.
Vivos CARE released a noninvasive, nonsurgical treatment of obstructive sleep apnea (OSA). This approach targets the underdeveloped anatomy of the airway, gradually remodeling the palate and upper jaw to prevent airway collapses during sleep. In about 12 months or less, this therapy helps patients achieve long-lasting results. Features include shorter treatment times, root cause resolution, patient comfort, and potentially lasting results. In addition to the CARE devices, Vivos offers a comprehensive and multidisciplinary approach to improve sleep health. Patients benefit from seamless access to home sleep tests, diagnoses, and telemedicine consultations with board-certified sleep physicians across all 50 states. Press release.